摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H-Imidazo[5,1-C][1,4]oxazine | 42341-20-8

中文名称
——
中文别名
——
英文名称
1H-Imidazo[5,1-C][1,4]oxazine
英文别名
——
1H-Imidazo[5,1-C][1,4]oxazine化学式
CAS
42341-20-8
化学式
C6H6N2O
mdl
MFCD18808201
分子量
122.12
InChiKey
PIPALTPIFNYWTO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    9
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    24.8
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • IMIDAZO COMPOUNDS
    申请人:Speedel Experimenta AG
    公开号:EP2007770A1
    公开(公告)日:2008-12-31
  • [EN] IMIDAZO COMPOUNDS<br/>[FR] COMPOSÉS IMIDAZO
    申请人:SPEEDEL EXPERIMENTA AG
    公开号:WO2007116099A1
    公开(公告)日:2007-10-18
    [EN] The application relates to novel heterocyclic compounds of the general formula (I) and salts, preferably pharmaceutically acceptable salts, thereof in which R, R1, R2, Q, m and n have the meanings explained in detail in the description, a process for their preparation and the use of these compounds as medicaments, in particular as aldosterone synthase inhibitors.
    [FR] L'application concerne de nouveaux composés hétérocycliques répondant à la formule générale (I), R, R1, R2, Q, m et n ayant les significations décrites en détail dans la description, et des sels, de préférence des sels pharmaceutiquement acceptables, desdits composés. L'invention concerne également un procédé permettant la préparation de ces composés et leur utilisation en tant que médicaments, en particulier en tant qu'inhibiteurs de l'aldostérone synthase.
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 4-(叔丁氧羰基)-4H-[1,4]恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-异丙基-4,4,6-三甲基-4H-1,3-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 2,4,4-三(三氟甲基)-6-全氟丁基-1,3,5-恶二嗪 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 3-(triethylsilyl)-2,5-dihydrofuran 4,4,6-trimethyl-2-propyl-4H-[1,3]oxazine 3-methyl-6,7,8,8a-tetrahydro-5H-cyclohepta[d]isoxazole 2,4-Dicyan-6-methyl-1,3-oxazepin 2,4-Dicyan-1,3-oxazepin 4-tert-Butyl-2,4,6-trimethyl-4H-pyran 3-(4,4,6-trimethyl-4H-[1,3]oxazin-2-yl)-propionitrile 4,4,6-Trimethyl-2-isopropenyl-1,3,4-oxazin 4a,7a-dihydro-4a,6-dimethyl-3-phenyl-4H-furo<2,3-e>-1,2-oxazine 3-methyl-1,4,6,9-tetraoxa-2-aza-5λ5-phospha-spiro[4.4]non-2-ene 6,8-Diethyl-1,1,2,2,3,3-hexafluoro-5-oxa-7,9-diaza-spiro[3.5]nona-6,8-diene (R)-4-Ethyl-3-((4S,5S)-4-methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-4H-pyridine-1-carboxylic acid methyl ester 4-Phenyl-2-pyrrolidin-1-yl-4,5-dihydro-furan-3-carbonitrile (S)-4-Ethyl-3-((4S,5S)-4-methoxymethyl-5-phenyl-4,5-dihydro-oxazol-2-yl)-4H-pyridine-1-carboxylic acid methyl ester (3S)-5-methyl-3-propan-2-yl-2,3-dihydro-1,4-oxazin-6-one dimethyl[η(10)-2,4-cyclopentadien-1-ylidene(dimethylsilylene)(3,4-di-tert-butyl-2,4-cyclopentadien-1-ylidene)]zirconium tert-butoxymethyl[η(10)-2,4-cyclopentadien-1-ylidene(dimethylsilylene)(3,4-di-tert-butyl-2,4-cyclopentadien-1-ylidene)]zirconium 2-Trimethylsilyl-4-methyl-4H-pyran methyl 3-methyl-6-trimethylsilylcyclohexa-1,4-dienecarboxylate 5-methyl-3-phenyl-(3ar,6ac)-3a,6a-dihydro-furo[2,3-d]isoxazole 2-methyl-4-chloro-3,6-dihydro-1,2-oxazine 4-n-butyl-3-<(N,N-diethylamino)methyl>-4,6-dimethyl-4H-pyran 3,5-diphenyl-(3ar,4at,7at,9ac)-3a,4a,7a,9a-tetrahydro-cyclohepta[2,1-d;4,5-d']diisoxazol-4-one 2-methyl-5-chloro-3,6-dihydro-1,2-oxazine 4,4-Di-tert-butyl-3-methyl-4H-<1,2>oxazet-N-oxid 6H-Pyrano[3,4-c]pyridine 6-ethoxy-3-phenyl-4-(trimethylsilylethynyl)-6H-1,2-oxazine 5,5-Dimethyl-2-oxazolin-4-spiro-3'-(1'-pyrrolin)